A practical reference on freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-02 and is reviewed periodically as new material appears.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
=== Pharmacodynamics === MDDMA shows reduced potency as a monoamine releasing agent and reuptake inhibitor compared to MDA and MDMA. It was 11-fold less potent than MDMA and 4-fold less potent than MDA as a serotonin releasing agent (SRA). Moreover, whereas MDA and MDMA are serotonin–norepinephrine–dopamine releasing agents (SNDRAs), MDDMA is a selective SRA along with ≥10-fold weaker dopamine and norepinephrine reuptake inhibition. The related drug MDTMA is completely inactive as a monoamine releasing agent, though it does still show very weak monoamine reuptake inhibition. Another related drug, dimethylamphetamine, is said to be a prodrug of methamphetamine and amphetamine, although it is much less potent and weaker than these drugs. (R)-MDDMA has been found be inactive as a serotonin releasing agent but to act as a partial agonist of the serotonin 5-HT2A and 5-HT2C receptors. Conversely, unlike MDMA, it was inactive as a serotonin 5-HT2B receptor agonist. In animal studies, (R)-MDDMA did not produce the head-twitch response, affect body temperature, or induce hyperlocomotion, and showed diminished or no prosocial effects. On the other hand, it produced psychoplastogenic effects mediated by serotonin 5-HT2 receptor activation as well as promoted fear extinction and induced antidepressant-like effects. It was concluded that (R)-MDDMA is a non-hallucinogenic psychoplastogen with improved safety compared to MDMA and (R)-MDMA.
March 14 – Marvin Scott died on March 14, 2021, in police custody at a correctional facility in McKinney, Texas. March 14–15 – A blizzard in Colorado brings over 24.1 inches (61 cm) of snow, passing a record of 23.8 inches (60 cm) set in 1982, to become the fourth largest recorded snowfall in Denver history and the largest since 2003 when the city received 31.8 inches (81 cm). It also leaves tens of thousands of people without power and some stranded in their cars after roads are closed. In Wyoming, over 31 inches (79 cm) were received in Cheyenne, and 52.5 inches (133 cm) in the Laramie Range. March 15 – Three people are killed and one injured when a small plane crashes in Pembroke Pines, Florida. March 16 COVID-19 pandemic: Massachusetts confirms its first case of the Lineage P.1 variant that originated in Brazil. 2021 Atlanta spa shootings – Eight people are killed and one is injured in a trio of shootings at spas in the Metro Atlanta, Georgia area. A suspect is arrested 150 miles south of Atlanta later that day and charged with eight counts of murder and one count of attempted murder two days later, March 18. March 17 The IRS announces that the deadline for Tax Day will be postponed to May 17. COVID-19 pandemic: North Dakota confirms its first four cases of the California variant of SARS-CoV-2. Additionally, seven cases of the UK variant are also confirmed. March 18–19 – The U.S. and China hold talks in Alaska to discuss relations, with topics ranging from Taiwanese security to Black Lives Matter.
Iron-deficiency anemia may be present without a person experiencing symptoms. It tends to develop slowly; therefore, the body has time to adapt, and the disease often goes unrecognized for some time. If symptoms present, patients may present with the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes), and the symptoms of feeling tired, weak, dizziness, lightheadedness, poor physical exertion, headaches, decreased ability to concentrate, cold hands and feet, cold sensitivity, increased thirst and confusion. None of these symptoms (or any of the others below) are sensitive or specific. In severe cases, shortness of breath can occur. Pica may also develop; of which consumption of ice, known as pagophagia, has been suggested to be the most specific for iron deficiency anemia. Other possible symptoms and signs of iron-deficiency anemia include:
Sources: en.wikipedia.org
This resulted in the publication of the report, The Double Bind: The Price of Being a Minority Woman in Science (1976) which made recommendations for recruiting and retaining minority women scientists. Daly was a member of the board of governors of the New York Academy of Sciences for two years. She was a fellow of the American Association for the Advancement of Science and of the American Cancer Society. Daly was designated as a career scientist by the Health Research Council of the City of New York. Daly retired in 1986 from the Albert Einstein College of Medicine, and in 1988 established a scholarship for African American chemistry and physics majors at Queens College in memory of her father. In 1999, she was recognized by the National Technical Association as one of the top 50 women in Science, Engineering and Technology.
== Medical uses == Hydroxychloroquine treats rheumatic disorders such as systemic lupus erythematosus, rheumatoid arthritis, and porphyria cutanea tarda, and certain infections such as Q fever and certain types of malaria. It is considered the first-line treatment for systemic lupus erythematosus. Certain types of malaria, resistant strains, and complicated cases require different or additional medication. Hydroxychloroquine blocks the effects of some chemicals released in autoimmune diseases, and is used to treat inflammatory conditions. It is widely used to treat primary Sjögren syndrome but does not appear to be effective. Hydroxychloroquine is widely used in the treatment of post-Lyme arthritis. It may have both an anti-spirochete activity and an anti-inflammatory activity, similar to the treatment of rheumatoid arthritis.
An enzyme-linked immunosorbent assay (ELISA) is one of the most common ways for detecting anti-U1 RNP antibodies in patient sera. In this procedure, purified or recombinant U1-RNP antigens are placed into microplate wells. After nonspecific binding sites are blocked, diluted patient serum is added to the wells and incubated. If specific autoantibodies are present, they can bind to the immobilized antigen. A secondary enzyme-conjugated anti-human IgG antibody is added, that it is followed by a substrate that produces a color change. This is read by spectrophotometry and compared to a standard curve to measure the levels of antibodies. Reference ranges are specific to each laboratory, and results must be interpreted in the context of clinical findings. This method is highly sensitive and frequently used to support diagnosis in patients with suspected MCTD or other connective tissue diseases. Other laboratory techniques include immunoblotting, immunoprecipitation, and multiplex immunoassays. Immunoblotting identifies antibodies directed against specific proteins within the U1 snRNP complex, while immunoprecipitation has traditionally been considered one of the most specific methods for confirming anti-U1 RNP antibodies. Multiplex immunoassays allow laboratories to detect several extracellular nuclear antigen antibodies at the same time, making them useful for evaluating those with suspected autoimmune diseases.
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.